Durable Clinical Response of Refractory Hepatocellular Carcinoma to Orally Administered Thalidomide
- 1 June 2000
- journal article
- case report
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 23 (3) , 319-21
- https://doi.org/10.1097/00000421-200006000-00023
Abstract
Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.Keywords
This publication has 11 references indexed in Scilit:
- Durable Clinical and Pathologic Response of Hepatocellular Carcinoma to Systemic and Hepatic Arterial Administration of Platinol, Recombinant Interferon α 2B, Doxorubicin, and 5-FluorouracilAmerican Journal of Clinical Oncology, 1999
- Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which Is Species-dependentBiochemical Pharmacology, 1998
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989
- Chemotherapy studies in primary liver cancer. A prospective randomized clinical trialCancer, 1978
- A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United StatesCancer, 1977
- Adenocarcinomas of stomach, pancreas, liver, and biliary tracts.Survival of 328 patients treated with fluoropyrimidine therapyCancer, 1974
- ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESISThe Journal of Experimental Medicine, 1971